Sign in
Taking peopleNo phase

Polaris 24 adjustable valve for people with hydrocephalus

Looks at how safe and well the Polaris 24 valve works in 126 patients.

Key facts

Who runs it
Sophysa
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Safety and Performance of the Polaris® 24 Adjustable Valve System in Hydrocephalus Patients' Treatment
Status
Recruiting
People taking part
126 people, planned
Started
4 Jun 2021
Expected to end
Jun 2033
Type of study
Observational
Record updated
27 January 2026

Who can take part

The trial is looking for people with hydrocephalus (fluid build-up in the brain) who have had the Polaris® 24 adjustable valve system implanted.

Sex
All sexes can join.
Disease stage
Hydrocephalus treated with the Polaris® 24 valve as a first shunt implant, as a replacement of another valve-based shunt, or after endoscopic ventriculostomy (EVT) failed.
Earlier treatment
People must have been implanted with the Polaris® 24 adjustable valve system.
Main reasons for not taking part
  • Confirmed or suspected infection along the shunt, or any infection anywhere in the body
  • Taking blood-thinning (anticoagulant) medicine
  • A bleeding disorder, or blood in the brain fluid (CSF)
  • A shunt draining into the heart (ventriculo-atrial) in people with heart defects from birth or other heart-lung malformations
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Patient implanted with the Polaris® 24 adjustable valve system for the following reasons:; Primo implant of a valve shunt-based derivation system, or as a; Replacement of another valve -based shunt system, or; Endoscopic ventriculostomy (EVT) failure
  • Patient having given his/her informed consent prior to inclusion in this study, as per local regulations

Who cannot take part

  • Confirmed or suspected infections along the length of the shunt (meningitis, ventriculitis, peritonitis, septicemia or bacteremia) or any infection present in any part of the body
  • Patient on anticoagulant therapy, or presenting with bleeding diathesis, or with haemorrhagic CSF, as the presence of blood in the system could lead to an obstruction in the system
  • Ventriculo-atrial shunts in patient suffering from congenital cardiopathies or other malformations of the cardio-pulmonary system

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Hydrocephalus

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The SAPPHYRE study is an ambispective (retrospective and prospective) PMCF study with the objective to evaluate the safety and performance of the Polaris® 24 adjustable valve system in the treatment of 126 patients with hydrocephalus.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Performance of the Polaris® 24 Adjustable Valve System in Hydrocephalus Patients' Treatment
Plain-language title
Polaris 24 adjustable valve for people with hydrocephalusGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT04746625, who can take part
Record updated
27 January 2026